National International Holding Company K.S.C.P Valuation

Is NIH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NIH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NIH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NIH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NIH?

Key metric: As NIH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NIH. This is calculated by dividing NIH's market cap by their current earnings.
What is NIH's PE Ratio?
PE Ratio	41x
Earnings	د.ك2.21m
Market Cap	د.ك90.60m

NIH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.2x
Enterprise Value/EBITDA	36x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does NIH's PE Ratio compare to its peers?

The above table shows the PE ratio for NIH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.2x
INVICTUS Invictus Investment	12.6x	n/a	د.إ2.0b
AMLAK Amlak Finance PJSC	32.1x	n/a	د.إ1.4b
WAHA Al Waha Capital PJSC	5.6x	n/a	د.إ2.8b
ALRAMZ Al Ramz Corporation Investment and Development P.J.S.C	30.3x	n/a	د.إ824.9m
NIH National International Holding Company K.S.C.P	41x	n/a	د.إ90.6m

Price-To-Earnings vs Peers: NIH is expensive based on its Price-To-Earnings Ratio (41x) compared to the peer average (20.2x).

Price to Earnings Ratio vs Industry

How does NIH's PE Ratio compare vs other companies in the Asian Diversified Financial Industry?

23 Companies	Price / Earnings	Estimated Growth	Market Cap

23 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: NIH is expensive based on its Price-To-Earnings Ratio (41x) compared to the Asian Diversified Financial industry average (20x).

Price to Earnings Ratio vs Fair Ratio

What is NIH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NIH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	41x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NIH's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.